114 related articles for article (PubMed ID: 8383497)
21. Model of Epstein-Barr virus infection of human thymocytes: expression of viral genome and impact on cellular receptor expression in the T-lymphoblastic cell line, HPB-ALL.
Paterson RL; Kelleher C; Amankonah TD; Streib JE; Xu JW; Jones JF; Gelfand EW
Blood; 1995 Jan; 85(2):456-64. PubMed ID: 7811999
[TBL] [Abstract][Full Text] [Related]
22. CR1(CD35) and CR2(CD21) complement C3 receptors are expressed on normal human thymocytes and mediate infection of thymocytes with opsonized human immunodeficiency virus.
Delibrias CC; Mouhoub A; Fischer E; Kazatchkine MD
Eur J Immunol; 1994 Nov; 24(11):2784-8. PubMed ID: 7957570
[TBL] [Abstract][Full Text] [Related]
23. Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies.
Tsoukas CD; Lambris JD
Eur J Immunol; 1988 Aug; 18(8):1299-302. PubMed ID: 2970972
[TBL] [Abstract][Full Text] [Related]
24. EBV binds to lymphocytes of transgenic mice that express the human CR2 gene.
Kearns-Jonker M; Monell-Torrens E; Abbasi F; Holers VM; Notkins AL; Sigounas G
Virus Res; 1997 Jul; 50(1):85-94. PubMed ID: 9255938
[TBL] [Abstract][Full Text] [Related]
25. Detection of the complement (CD21)/Epstein-Barr virus receptor in human lacrimal gland and ocular surface epithelia.
Levine J; Pflugfelder SC; Yen M; Crouse CA; Atherton SS
Reg Immunol; 1990-1991; 3(4):164-70. PubMed ID: 1966579
[TBL] [Abstract][Full Text] [Related]
26. C3d and Epstein-Barr virus (CR2/CD21 ligands) stimulate cells of an HTLV-I line, MT-2.
Kuraya M; Sato T; Fujita T
Microbiol Immunol; 1995; 39(2):145-51. PubMed ID: 7783687
[TBL] [Abstract][Full Text] [Related]
27. Epstein-Barr virus/C3d receptor (CR2, CD21) activated by its extracellular ligands regulates pp105 phosphorylation through two distinct pathways.
Bouillie S; Barel M; Drane P; Cassinat B; Balbo M; Holers VM; Frade R
Eur J Immunol; 1995 Sep; 25(9):2661-7. PubMed ID: 7589142
[TBL] [Abstract][Full Text] [Related]
28. Monoclonal and anti-idiotypic anti-EBV/C3d receptor antibodies detect two binding sites, one for EBV and one for C3d on glycoprotein 140, the EBV/C3dR, expressed on human B lymphocytes.
Barel M; Fiandino A; Delcayre AX; Lyamani F; Frade R
J Immunol; 1988 Sep; 141(5):1590-5. PubMed ID: 2842398
[TBL] [Abstract][Full Text] [Related]
29. Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor, CD21).
Esparza I; Becherer JD; Alsenz J; De la Hera A; Lao Z; Tsoukas CD; Lambris JD
Eur J Immunol; 1991 Nov; 21(11):2829-38. PubMed ID: 1834472
[TBL] [Abstract][Full Text] [Related]
30. Characterization of a T-lymphocyte Epstein-Barr virus/C3d receptor (CD21).
Fingeroth JD; Clabby ML; Strominger JD
J Virol; 1988 Apr; 62(4):1442-7. PubMed ID: 2831405
[TBL] [Abstract][Full Text] [Related]
31. Redox control of EBV infection: prevention by thiol-dependent modulation of functional CD21/EBV receptor expression.
Nishinaka Y; Nakamura H; Okada N; Okada H; Yodoi J
Antioxid Redox Signal; 2001 Dec; 3(6):1075-87. PubMed ID: 11813981
[TBL] [Abstract][Full Text] [Related]
32. The Epstein-Barr virus receptor is distinct from the C3 receptor.
Wells A; Koide N; Stein H; Gerdes J; Klein G
J Gen Virol; 1983 Feb; 64 (Pt 2)():449-53. PubMed ID: 6300295
[TBL] [Abstract][Full Text] [Related]
33. EBV attachment stimulates FHOS/FHOD1 redistribution and co-aggregation with CD21: formin interactions with the cytoplasmic domain of human CD21.
Gill MB; Roecklein-Canfield J; Sage DR; Zambela-Soediono M; Longtine N; Uknis M; Fingeroth JD
J Cell Sci; 2004 Jun; 117(Pt 13):2709-20. PubMed ID: 15138285
[TBL] [Abstract][Full Text] [Related]
34. Characterization of a 70-kDa, EBV gp350/220-binding protein on HSB-2 T cells.
Hedrick JA; Lao Z; Lipps SG; Wang Y; Todd SC; Lambris JD; Tsoukas CD
J Immunol; 1994 Nov; 153(10):4418-26. PubMed ID: 7963519
[TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus (EBV) infection of murine L cells expressing recombinant human EBV/C3d receptor.
Ahearn JM; Hayward SD; Hickey JC; Fearon DT
Proc Natl Acad Sci U S A; 1988 Dec; 85(23):9307-11. PubMed ID: 2848261
[TBL] [Abstract][Full Text] [Related]
36. Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection.
Nemerow GR; Mullen JJ; Dickson PW; Cooper NR
J Virol; 1990 Mar; 64(3):1348-52. PubMed ID: 2154612
[TBL] [Abstract][Full Text] [Related]
37. Patterned entry and egress by Epstein-Barr virus in polarized CR2-positive epithelial cells.
Chodosh J; Gan Yj; Holder VP; Sixbey JW
Virology; 2000 Jan; 266(2):387-96. PubMed ID: 10639323
[TBL] [Abstract][Full Text] [Related]
38. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes.
Fischer E; Delibrias C; Kazatchkine MD
J Immunol; 1991 Feb; 146(3):865-9. PubMed ID: 1703182
[TBL] [Abstract][Full Text] [Related]
39. Immunobiology of CR2, the B lymphocyte receptor for Epstein-Barr virus and the C3d complement fragment.
Cooper NR; Moore MD; Nemerow GR
Annu Rev Immunol; 1988; 6():85-113. PubMed ID: 2838050
[No Abstract] [Full Text] [Related]
40. Superinfection of epithelial hybrid cells (D98/HR-1, NPC-KT, and A2L/AH) with Epstein-Barr virus and the relationship to the C3d receptor.
Takimoto T; Sato H; Ogura H; Miyawaki T; Glaser R
Cancer Res; 1986 May; 46(5):2541-4. PubMed ID: 3008992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
